All > Boston > Endometrial Cancer

Ribociclib for Carcinosarcoma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Carcinosarcoma+8 MoreRibociclib - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer drug to see if it is safe and works well against cancer cells.

Eligible Conditions
  • Carcinosarcoma
  • Advanced Solid Tumors
  • Esophageal Cancer
  • Endometrial Cancer
  • HER2-negative Breast Cancer
  • Stomach Cancer
  • Estrogen Receptor Positive Breast Cancer
  • Ovarian Cancer
  • CCNE1 Amplification

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Ribociclib
1
Palbociclib
1
DAN-222

Study Objectives

5 Primary · 26 Secondary · Reporting Duration: Up to 43 months

Approximately 21 months
[Phase 1] Accumulation ratio (R)
[Phase 1] Apparent oral clearance(CL/F)
[Phase 1] Apparent volume of distribution (Vz/F)
[Phase 1] Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval (AUC0-24)
[Phase 1] Determine the maximum tolerated dose (MTD) of BLU-222
[Phase 1] Determine the recommended Phase 2 dose (RP2D) of BLU-222
[Phase 1] Maximum plasma drug concentration (Cmax)
[Phase 1] Overall response rate (ORR)
[Phase 1] Rate and severity of adverse events
[Phase 1] Terminal elimination half-life (t½)
[Phase 1] Time of last quantifiable plasma drug concentration (Tlast)
[Phase 1] Time to maximum plasma drug concentration (Tmax)
[Phase 1] To assess treatment-induced modulation of cyclin E/CDK2 pathway biomarkers
[Phase 1] Trough concentration (Ctrough)
[Phase 2] Overall response rate (ORR)
[Phase 2] Rate and severity of adverse events
Approximately 43 months
[Phase 1 and Phase 2] Change in CA-125 levels
[Phase 1 and Phase 2] Clinical benefit rate (CBR)
[Phase 1 and Phase 2] Disease control rate (DCR)
[Phase 1 and Phase 2] Duration of Response (DOR)
[Phase 2] Overall survival (OS)
[Phase 2] Progression free survival (PFS)
Up to 43 months
[Phase 1 and Phase 2] Accumulation ratio (R)
[Phase 1 and Phase 2] Apparent oral clearance(CL/F)
[Phase 1 and Phase 2] Apparent volume of distribution (Vz/F)
[Phase 1 and Phase 2] Area under the plasma concentration versus time curve from time 0 to the end of the dosing interval (AUC0-24)
[Phase 1 and Phase 2] Maximum plasma drug concentration (Cmax)
[Phase 1 and Phase 2] Terminal elimination half-life (t½)
[Phase 1 and Phase 2] Time of last quantifiable plasma drug concentration (Tlast)
[Phase 1 and Phase 2] Time to maximum plasma drug concentration (Tmax)
[Phase 1 and Phase 2] Trough concentration (Ctrough)

Trial Safety

Safety Progress

1 of 3

Similar Trials

1
Ribociclib
1
Palbociclib
1
DAN-222

Side Effects for

Ribociclib + Letrozole + Goserelin/Leuprolide
61%Neutropenia
36%Nausea
23%Fatigue
21%Arthralgia
21%Diarrhoea
20%Alopecia
20%Vomiting
19%Asthenia
19%Neutrophil count decreased
18%Anaemia
18%Leukopenia
17%Constipation
16%Alanine aminotransferase increased
15%Cough
15%Hot flush
14%Aspartate aminotransferase increased
14%Headache
13%Back pain
13%Pruritus
12%Decreased appetite
12%Pyrexia
12%Rash
10%White blood cell count decreased
9%Oedema peripheral
9%Stomatitis
8%Pain in extremity
8%Insomnia
8%Thrombocytopenia
8%Dyspnoea
7%Bone pain
7%Electrocardiogram QT prolonged
7%Dry skin
7%Abdominal pain
7%Abdominal pain upper
7%Dyspepsia
7%Dizziness
7%Hypertension
6%Upper respiratory tract infection
6%Musculoskeletal pain
6%Urinary tract infection
6%Nasopharyngitis
6%Blood creatinine increased
6%Myalgia
5%Lymphopenia
1%Febrile neutropenia
1%Pneumonia
1%Pleural effusion
1%Pulmonary embolism
This histogram enumerates side effects from a completed 2022 Phase 3 trial (NCT02941926) in the Ribociclib + Letrozole + Goserelin/Leuprolide ARM group. Side effects include: Neutropenia with 61%, Nausea with 36%, Fatigue with 23%, Arthralgia with 21%, Diarrhoea with 21%.

Trial Design

4 Treatment Groups

BLU-222 Monotherapy
1 of 4
BLU-222 + fulvestrant
1 of 4
BLU-222 + Ribociclib + Fulvestrant
1 of 4
BLU-222 + Carboplatin
1 of 4

Experimental Treatment

366 Total Participants · 4 Treatment Groups

Primary Treatment: Ribociclib · No Placebo Group · Phase 1 & 2

BLU-222 MonotherapyExperimental Group · 2 Interventions: Fulvestrant, BLU-222 · Intervention Types: Drug, Drug
BLU-222 + fulvestrantExperimental Group · 2 Interventions: Fulvestrant, BLU-222 · Intervention Types: Drug, Drug
BLU-222 + Ribociclib + FulvestrantExperimental Group · 3 Interventions: Ribociclib, Fulvestrant, BLU-222 · Intervention Types: Drug, Drug, Drug
BLU-222 + CarboplatinExperimental Group · 2 Interventions: BLU-222, Carboplatin · Intervention Types: Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Ribociclib
2018
Completed Phase 3
~8170
Fulvestrant
2011
Completed Phase 3
~3810
Carboplatin
2014
Completed Phase 3
~7230

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to 43 months

Who is running the clinical trial?

Blueprint Medicines CorporationLead Sponsor
27 Previous Clinical Trials
4,523 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top